Subject: EARNINGS PROJECTIONS
Milestone Scientific Provides Business Update for the Second Quarter of 2017
LIVINGSTON, NJ --(Marketwired - August 14, 2017) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a medical company that develops and commercializes a growing portfolio of proprietary injection technologies, today provided a business update and announced financial results for the second quarter and six months ending June 30, 2017.
Daniel Goldberger, Chief Executive Officer of Milestone Scientific stated, "I am pleased to report that the Wand Dental business continues to grow profitably and we are making steady progress towards commercializing our first medical instrument following successful FDA marketing clearance of the CompuFlotm Epidural Instrument earlier this year. We recently announced treatment of our first patient in the U.S. with the CompuFlotm Epidural Instrument at the University of Miami Hospital. Outside the U.S., we are actively recruiting distribution partners for the CompuFlotm Epidural Instrument in all the important international markets."
"Our Wand Dental business continues to strengthen, highlighted by a 70% increase in domestic handpiece sales, as we launched several promotional programs through the exclusive product sales team at Henry Schein, our distributor for the U.S. and Canada. We believe these marketing initiatives along with further investments in education and research activities with our worldwide team of key opinion leaders should build market awareness and serve to accelerate revenue growth in the second half of 2017 and throughout 2018."
Revenue for the three months ended June 30, 2017 was $2.5 million versus $2.4 million for the second quarter of 2016. The increase in total revenue by approximately 6% was primarily related to the increase in domestic sales. Domestic sales increased by approximately $517,000 in 2017. International sales decreased by approximately $365,000 over the same period in 2016 principally due to a reduction in shipments of handpieces to Milestone China. The decrease is due to Milestone China working through its current inventories and adjusting its business model. Gross profit for the second quarter of 2017 was $1.7 million or 65% of revenue versus $1.6 million or 67% of revenue in the second quarter of 2016. Net loss for the second quarter of 2017 was $(1.5) million, or $(0.05) per share, versus net loss of $(1.6) million, or $(0.06) per share, for the comparable period in 2016.
Revenue for the six months ended June 30, 2017 was $6.2 million versus $5.8 million for the second quarter of 2016. The increase in total revenue by approximately 6% was primarily related to increased handpiece sales in the United States. Domestic sales increased by approximately $499,000 in 2017. International sales decreased by approximately $123,000 over the same period in 2016 principally due to a reduction in shipments of handpieces to Milestone China. Gross profit for the second quarter of 2017 was $3.9 million or 63% of revenue versus $3.7 million or 63% of revenue in the second quarter of 2016. Net loss for the second quarter of 2017 was $(2.0) million, or $(0.06) per share, versus net loss of $(2.4) million, or $(0.10) per share, for the comparable period in 2016.
Conference Call
Milestone Scientific's executive management team will host a conference call at 8:00 AM Eastern Time on Tuesday, August 15, 2017 to discuss the Company's financial results for the second quarter ended June 30, 2017, as well as the Company's corporate progress and other developments.
The conference call will be available via telephone by dialing toll free 866-564-2842 and entering the pass code 1085396 or on the company's website at www.milestonescientific.com. For those unable to participate at that time, a replay of the call will be archived on the company's website or can be accessed by dialing 888-203-1112 and entering the pass code 1085396. The replay will be available for 90 days.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
(tables follow)
| MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (Unaudited) | ||||||||
| June 30, 2017 | December 31, 2016 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 2,945,631 | $ | 3,602,229 | ||||
| Accounts receivable, net of allowance for doubtful accounts of $10,000 as of June 30, 2017 and $5,000 as of December 31, 2016 | 1,419,731 | 802,384 | ||||||
| Accounts receivable from related party | 356,400 | 2,714,600 | ||||||
| Other receivable | - | 10,000 | ||||||
| Notes receivable, financing transaction short term | 500,000 | - | ||||||
| Inventories | 4,498,371 | 4,602,719 | ||||||
| Advances on contracts | 851,504 | 700,900 | ||||||
| Deferred cost | 181,116 | 620,041 | ||||||
| Prepaid expenses and other current assets | 746,491 | 291,929 | ||||||
| Total current assets | 11,499,244 | 13,344,802 | ||||||
| Furniture, fixtures & equipment net of accumulated depreciation of $707,167 as of June 30, 2017 and $659,144 as of December 31, 2016 | 170,552 | 159,026 | ||||||
| Patents, net of accumulated amortization of $809,332 as of June 30,2017 and $717,086 as of December 31, 2016 | 625,092 | 660,457 | ||||||
| Notes receivable, financing transaction long term | 775,000 | - | ||||||
| Other assets | 26,878 | 17,355 | ||||||
| Total assets | $ | 13,096,766 | $ | 14,181,640 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 985,736 | $ | 1,341,207 | ||||
| Accounts payable related party | 381,432 | 1,235,052 | ||||||
| Accrued expenses and other payables | 1,652,144 | 1,436,262 | ||||||
| Deferred profit, related party | 659,931 | 630,990 | ||||||
| Deferred revenue | 356,400 | 1,001,800 | ||||||
| Total current liabilities | 4,035,643 | 5,645,311 | ||||||
| Deferral from financing transaction | 1,400,000 | - | ||||||
| Total liabilities | 5,435,643 | 5,645,311 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders' Equity | ||||||||
| Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, 33,333 shares held in the treasury, and 7,000 shares issued and outstanding as June 30, 2017 and December 31, 2016 | 7 | 7 | ||||||
| Common stock, par value $.001; authorized 50,000,000 shares; 31,376,699 shares issued, 1,361,071 shares to be issued and 31,343,366 shares outstanding as of June 30, 2017; 30,457,224 shares issued, 1,270,481 shares to be issued and 30,423,891 shares outstanding as of December 31, 2016 | 32,736 | 31,720 | ||||||
| Additional paid-in capital | 83,600,384 | 82,761,503 | ||||||
| Accumulated deficit | (75,365,184 | ) | (73,381,491 | ) | ||||
| Treasury stock, at cost, 33,333 shares | (911,516 | ) | (911,516 | ) | ||||
| Total Milestone Scientific Inc. stockholders' equity | 7,356,427 | 8,500,223 | ||||||
| Noncontrolling interest | 304,696 | 36,106 | ||||||
| Total Equity | 7,661,123 | 8,536,329 | ||||||
| Total liabilities and stockholders' equity | $ | 13,096,766 | $ | 14,181,640 | ||||
| MILESTONE SCIENTIFIC INC. |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|
(Unaudited)
|
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue | ||||||||||||||||
| Product sales, net | $ | 2,523,750 | $ | 2,371,710 | $ | 6,212,738 | $ | 5,836,196 | ||||||||
| Cost of products sold | 873,586 | 789,801 | 2,275,871 | 2,157,990 | ||||||||||||
| Gross profit | 1,650,164 | 1,581,909 | 3,936,867 | 3,678,206 | ||||||||||||
| Selling, general and administrative expenses | 3,082,534 | 3,290,998 | 5,790,161 | 6,292,109 | ||||||||||||
| Research and development expenses | 120,065 | 309,335 | 225,080 | 452,780 | ||||||||||||
| Total operating expenses | 3,202,599 | 3,600,333 | 6,015,241 | 6,744,889 | ||||||||||||
| Loss from operations | (1,552,435 | ) | (2,018,424 | ) | (2,078,374 | ) | (3,066,683 | ) | ||||||||
| Other (expenses) | (1,024 | ) | (1,004 | ) | (1,763 | ) | (1,936 | ) | ||||||||
| Interest income | 2,154 | - | 2,442 | - | ||||||||||||
| Loss before provision for income tax and equity in net earnings of equity investments | (1,551,305 | ) | (2,019,428 | ) | (2,077,695 | ) | (3,068,619 | ) | ||||||||
| Provision for income tax | (4,664 | ) | (16,791 | ) | (11,865 | ) | (63,624 | ) | ||||||||
| Loss before equity in net earnings of equity investments | (1,555,969 | ) | (2,036,219 | ) | (2,089,560 | ) | (3,132,243 | ) | ||||||||
| Profit or (loss) on equity investment in China Joint Venture | 15,460 | (57,882 | ) | (28,941 | ) | (222,719 | ) | |||||||||
| Profit or (loss)in equity investments | 15,460 | (57,882 | ) | (28,941 | ) | (222,719 | ) | |||||||||
| Net loss | (1,540,509 | ) | (2,094,101 | ) | (2,118,501 | ) | (3,354,962 | ) | ||||||||
| Net loss attributable to noncontrolling interests | (61,684 | ) | (507,262 | ) | (134,808 | ) | (976,308 | ) | ||||||||
| Net loss attributable to Milestone Scientific Inc. | $ | (1,478,825 | ) | $ | (1,586,839 | ) | $ | (1,983,693 | ) | $ | (2,378,654 | ) | ||||
| Net loss per share applicable to common stockholders -- | ||||||||||||||||
| Basic | $ | (0.05 | ) | $ | (0.06 | ) | $ | (0.06 | ) | $ | (0.10 | ) | ||||
| Diluted | $ | (0.05 | ) | $ | (0.06 | ) | $ | (0.06 | ) | $ | (0.10 | ) | ||||
| Weighted average shares outstanding and to be issued -- | ||||||||||||||||
| Basic | 32,399,997 | 25,989,857 | 32,122,482 | 24,362,441 | ||||||||||||
| Diluted | 32,399,997 | 25,989,857 | 32,122,482 | 24,362,441 | ||||||||||||
These press releases may also interest you
|
News published on and distributed by:
